PA
SGMT icon

Parallel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Parallel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.56K Hold
849
– – ﹤0.01% 3109
2026
Q1 		$4.44K Hold
849
– – ﹤0.01% 3078
2025
Q4 		$5.03K Buy
+849
New +$6.1K ﹤0.01% 2841

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Parallel Advisors's SGMT Position: Q2 2026 in Review

Parallel Advisors held its Sagimet Biosciences (SGMT) position steady in Q2 2026 at 849 shares worth $6.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3109.

Parallel Advisors first reported a position in SGMT in Q4 2025 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Parallel Advisors held 849 shares of Sagimet Biosciences worth $6.56K as of Q2 2026.
  • Parallel Advisors left its Sagimet Biosciences share count unchanged in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3109 holding.
  • Parallel Advisors first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.